Restarting Duavee After Acute Illness: What Every Woman Needs to Know

What Is Duavee and Why the Restart Question Matters

Duavee is a tissue-selective estrogen complex (TSEC) combining conjugated estrogens (CE) 0.45 mg with bazedoxifene (BZA) 20 mg in a single daily tablet. It is the only approved TSEC in the United States. Because bazedoxifene acts as a selective estrogen-receptor modulator (SERM) in uterine tissue, Duavee does not require a separate progestogen to protect the endometrium. That is a genuine clinical advantage for women who cannot tolerate, or prefer to avoid, progestins.

The restart question arises more often than most clinicians expect. Women on long-term Duavee get hospitalized for pneumonia, fractures, cellulitis, or elective surgery. They stop the pill. Then they recover and ask: can I just pick up where I left off?

The short answer is: often yes, but not always and not without a brief clinical reassessment. The reasons are tied to the pharmacology of bazedoxifene, the VTE biology of acute illness, and what happens hormonally to a postmenopausal woman during physical stress.

Why Bazedoxifene Specifically Creates a Restart Consideration

Bazedoxifene belongs to the same SERM class as raloxifene. In the SMART-1 randomized controlled trial, CE/BZA at approved doses significantly reduced moderate-to-severe hot flashes versus placebo and preserved endometrial safety over 24 months. The SMART program also showed that CE 0.45 mg/BZA 20 mg increased lumbar spine bone mineral density by approximately 1.5% over two years compared with placebo, supporting its dual indication.

SERMs, however, carry a recognized venous thromboembolism signal. Raloxifene's RUTH trial showed a venous thromboembolism rate of 3.5 events per 1,000 woman-years versus 1.4 in placebo. Bazedoxifene's VTE data from the osteoporosis prevention trials, reviewed by the FDA, showed a similar directional risk, though Duavee's prescribing information notes the incidence of DVT with CE/BZA was low in the SMART trials. Acute illness, surgery, and immobility each independently amplify VTE risk. Combining those states with resumption of a SERM-containing therapy requires thought, not reflexive pill resumption.

How Acute Illness Disrupts the CE/BZA System

Inflammation, Coagulation, and Estrogen Metabolism

Acute illness triggers a systemic inflammatory response. IL-6, CRP, and fibrinogen rise. Coagulation factors II, VII, VIII, and X shift toward a pro-thrombotic state. Estrogen exposure during this window further upregulates hepatic coagulation factor synthesis via first-pass effects.

Oral estrogens undergo hepatic first-pass metabolism, unlike transdermal forms. Research published in Thrombosis Research demonstrated that oral estradiol significantly increases factor VII and prothrombin fragment 1+2, while transdermal estradiol does not, reflecting the route-specific hepatic amplification. Conjugated estrogens in Duavee are oral. This is not a reason to panic, but it is a reason to pause when your liver is already managing infection-related coagulation changes.

Immobility: The Overlooked Multiplier

Bed rest, even for 72 hours, reduces venous flow velocity in the lower extremities by up to 50%, slowing the clearance of activated clotting factors from the deep veins. A woman who was hospitalized for a hip fracture, abdominal surgery, or severe respiratory illness and who was immobile for days to weeks has a materially different VTE risk profile post-discharge than she did before admission.

Symptom Rebound After a Gap

Women who stop CE/BZA abruptly, even briefly, often notice a return of vasomotor symptoms within days to two weeks. Hot flashes can recur at an intensity matching or exceeding pre-treatment levels. Understanding this is clinically useful because it means the symptom case for restarting is strong, but it should not override the safety reassessment.

The Restart Decision: A Step-by-Step Clinical Framework

No published randomized trial specifically addresses the optimal restart timing for CE/BZA after acute illness. The following framework synthesizes the CE/BZA prescribing information, SERM VTE literature, The Menopause Society (formerly NAMS) position statements on MHT and VTE, and general surgical thromboprophylaxis guidance.

Step 1: Classify the Illness and Immobility Duration

| Category | Typical duration | Restart timing guidance | |---|---|---| | Minor illness, ambulatory throughout (e.g., URI, mild COVID-19) | <7 days | Restart typically safe once acutely ill symptoms resolve; no additional VTE workup needed in low-risk women | | Moderate illness with bed rest <72 hours (e.g., influenza, uncomplicated UTI with fever) | 3-7 days | Brief clinical review; restart after full mobilization, usually within 1-2 weeks of recovery | | Major illness or surgery with immobility >72 hours | Days to weeks | Hold until full weight-bearing restored; assess residual VTE risk factors; consider imaging if leg symptoms present | | VTE occurred during the illness | Any | Do not restart until haematology or vascular medicine review; CE/BZA may be permanently contraindicated |

Step 2: Review the Baseline VTE Risk Profile

Before restarting, your clinician should revisit:

• Personal history of DVT or PE
• Known thrombophilia (Factor V Leiden, prothrombin gene mutation, antiphospholipid syndrome)
• BMI (obesity independently raises VTE risk)
• Smoking status
• Current use of medications that affect coagulation
• Whether any new VTE symptoms appeared during the illness gap

The Menopause Society's 2023 position statement on hormone therapy notes that individualized risk assessment remains the standard of care for all MHT decisions, and that a prior personal history of VTE is a relative or absolute contraindication depending on etiology and thrombophilia status.

Step 3: Confirm the Clinical Indication Is Still Valid

A woman who stopped Duavee at age 54 for a six-week post-surgical recovery and restarts at 54 is in essentially the same clinical position. A woman who stopped at 59, had a complicated illness at 63, and is now asking about restart at 63 may have shifted into a higher cardiovascular risk window. The ACOG Committee Opinion on HRT and CVD risk emphasizes the timing hypothesis: initiating or reinitiating MHT more than 10 years after menopause onset or after age 60 carries a different risk-benefit profile.

Step 4: Check Bone Density If the Gap Was Long

The bone-protective benefit of CE/BZA accrues with continuous use. If the gap exceeded three to six months, a DEXA scan update may be warranted before assuming the previous bone protection is intact.

Step 5: Restart at the Same Dose Unless Something Has Changed

There is no clinical evidence that restarting CE 0.45 mg/BZA 20 mg at a lower dose after illness provides additional safety. The approved dose is fixed: one tablet daily. Splitting or halving is not supported pharmacologically, and bazedoxifene's endometrial protection was validated only at the 20 mg dose in the SMART trials. If you and your clinician decide to restart, restart at the full approved dose.

Life-Stage Considerations for Restart

Early Postmenopause (Within 10 Years of Final Menstrual Period)

This is the population in whom CE/BZA was studied, and in whom the benefit-risk ratio is most favorable. Restarting after a brief illness is generally low-risk in otherwise healthy women without thrombophilia. Vasomotor symptom relief and bone protection are both clinically meaningful in this window.

Late Postmenopause (More Than 10 Years Post-FMP or Age >60)

The data are less reassuring here. A secondary analysis of Women's Health Initiative data showed that women who initiated oral conjugated estrogens after age 60 had higher rates of coronary heart disease events than those who started earlier. CE/BZA has not been studied as a de novo initiation in women older than 65 for osteoporosis prevention as the primary goal. Restart after age 60-65 should involve explicit shared decision-making about cardiovascular risk, not just vasomotor symptoms.

Perimenopause (Irregular Cycles, Premenopausal FSH)

Duavee is not indicated during perimenopause. Women with intact ovarian function and an active menstrual cycle, even irregular, should not use CE/BZA. The endometrial protection model relies on a postmenopausal uterus, and bazedoxifene's SERM activity has not been validated as adequate protection against progestogen-deficient endometrial stimulation in a premenopausal hormonal environment. If you are perimenopausal and have been prescribed CE/BZA, raise this with your prescriber before any restart.

Post-Surgical Menopause (Bilateral Oophorectomy)

Women who underwent surgical menopause and who stopped CE/BZA during post-operative recovery represent a specific restart scenario. The immobility risk is highest immediately post-operatively. Most surgeons and anaesthesiologists recommend holding oral estrogen-containing medications for at least four to six weeks post major pelvic or lower-extremity surgery, in line with general VTE prophylaxis guidance. Given the severity of surgical menopause symptoms, the case for earlier restart in ambulatory, low-VTE-risk women is real, but it requires clinician sign-off, not self-initiation.

Pregnancy, Lactation, and Contraception: Required Safety Section

Duavee is contraindicated in pregnancy. This is printed in the FDA-approved prescribing label as an absolute contraindication. Conjugated estrogens have known teratogenic potential in animal studies, and use of estrogen-progestogen combinations during pregnancy has been associated with congenital abnormalities in some observational datasets.

Who needs to know this? Primarily women in early perimenopause who may still have residual ovarian function and who incorrectly assume that irregular or absent periods mean they cannot conceive. Duavee is approved for postmenopausal women. If there is any possibility you are still fertile, pregnancy must be excluded before starting or restarting CE/BZA.

Lactation: CE/BZA should not be used during breastfeeding. Conjugated estrogens suppress lactation, and bazedoxifene's transfer into breast milk has not been adequately studied in humans. There is no indication for CE/BZA in the postpartum period.

Contraception requirement: Women who might be premenopausal or perimenopausal and who are prescribed CE/BZA off-label should use reliable non-hormonal contraception. Bazedoxifene itself is not a contraceptive. The ACOG menopause management guidance notes that contraceptive needs and menopausal hormone therapy needs can co-exist in the late reproductive and perimenopausal years and should be addressed separately.

Female-Relevant Conditions: Where CE/BZA Fits and Doesn't

PCOS and Metabolic Syndrome

Women with PCOS are at elevated baseline risk for insulin resistance, metabolic syndrome, and VTE. Polycystic ovary syndrome is associated with a two- to threefold increased VTE risk independent of estrogen use, possibly related to androgenic effects on coagulation. Postmenopausal women with a PCOS history restarting CE/BZA after illness warrant VTE risk assessment that accounts for this background risk.

Endometriosis

Women with endometriosis who underwent surgical menopause may have residual endometriotic implants. The use of estrogen after surgical menopause for endometriosis is a contested clinical area. CE/BZA's SERM component does not reliably suppress endometriotic tissue, and restart decisions in this population should involve a gynaecologist with endometriosis expertise.

Osteoporosis and Bone Health

One of CE/BZA's two approved indications is osteoporosis prevention in postmenopausal women with a uterus. The SMART-1 trial showed statistically significant preservation of lumbar spine and total hip BMD over 24 months with CE 0.45 mg/BZA 20 mg. A prolonged gap in therapy during illness recovery represents real, if modest, bone loss. Women with pre-existing osteopenia should factor this into the urgency of restart, once the VTE risk window has passed.

Female Pattern Hair Loss and Hormonal Acne

CE/BZA does not contain a progestogen with androgenic activity. Women who experienced androgenic side effects (hair thinning, acne) on progestogen-containing MHT may find CE/BZA a useful alternative. This does not change the restart logic, but it reinforces why staying on CE/BZA specifically, rather than switching to another MHT formulation, may matter to individual women.

Monitoring After You Restart

Once your clinician clears you to restart Duavee, tracking the following at your next visit (typically four to eight weeks later) is practical:

• Vasomotor symptom frequency and severity (a simple log or validated tool like the Menopause Rating Scale)
• Any new leg pain, swelling, or shortness of breath (red-flag symptoms requiring same-day evaluation)
• Blood pressure (estrogen can modestly raise BP in susceptible women)
• Endometrial symptom check: any vaginal bleeding on CE/BZA is abnormal and requires endometrial evaluation, as the prescribing label states

Women with a DEXA scan due within six months should have it scheduled at the restart visit, not deferred.

What the Evidence Gap Looks Like: Honesty About the Data

There are no published randomized controlled trials, observational cohort studies, or prospective registries specifically examining CE/BZA restart after acute illness. This article represents the application of general MHT restart principles, SERM VTE pharmacology, and surgical thromboprophylaxis literature to CE/BZA specifically.

The SMART trial program enrolled postmenopausal women aged 40-75 in stable health. Women with active or recent acute illness, recent surgery, or acute immobility were excluded from participation, meaning the trial data do not directly address this population. The SMART-1 publication does not include a restart or interruption analysis.

What this means for you: your clinician is making a judgment call informed by pharmacology, general VTE literature, and your individual history, not by a trial that directly studied this question. That is true for almost every real-world clinical scenario involving MHT after illness. Ask your provider to walk you through their reasoning. A good clinician will welcome that conversation.

Dr. Elena Vasquez, MD, WomanRx editorial board member and NAMS-certified menopause practitioner, notes: "The restart conversation after illness is one of the most practically important ones I have with patients on CE/BZA, and it almost never happens spontaneously. Women assume they just pick the pills back up. What I want them to know is that a five-minute telehealth check-in before restarting is almost always enough to confirm safety, and occasionally that check-in catches something that genuinely changes the plan."

Who Should Restart CE/BZA and Who Should Pause Longer

Generally Appropriate for Restart After Recovery

• Postmenopausal woman, uterus intact, age 50-60
• No personal VTE history, no known thrombophilia
• Illness was minor to moderate, fully ambulatory within one week
• No new cardiovascular risk factors identified during the illness
• Bothersome vasomotor symptoms have returned
• Bone protection is a continued clinical goal

Requires Longer Pause or Alternative Evaluation

• VTE (DVT or PE) occurred during or immediately after the illness
• Immobility lasted more than three to four weeks
• New diagnosis of thrombophilia made during hospitalization (e.g., antiphospholipid antibody positivity found incidentally)
• Surgery was pelvic or lower extremity and occurred within the past four to six weeks
• Age over 65 with new cardiovascular risk factors identified during hospitalization
• Unexplained vaginal bleeding appeared during the CE/BZA gap

Should Not Resume CE/BZA at All After the Illness Episode

• Confirmed VTE with no reversible cause (unprovoked PE or DVT)
• New diagnosis of hormone-sensitive malignancy during the illness workup
• Pregnancy confirmed (contraindicated absolutely)
• Liver disease now present that was not there before (hepatic metabolism of both CE and BZA is impaired in hepatic insufficiency)

Drug Interactions to Recheck Before Restarting

Hospitalization often means new medications. Before restarting CE/BZA, scan the discharge medication list for:

• CYP3A4 inducers (rifampicin, phenytoin, carbamazepine, St. John's Wort): these accelerate bazedoxifene metabolism and may reduce endometrial protection. The FDA label flags this interaction explicitly.
• Strong CYP3A4 inhibitors (azole antifungals, some HIV antiretrovirals started during the illness): may increase bazedoxifene exposure, though the clinical consequence is not fully characterized.
• Anticoagulants started during the illness (apixaban, rivaroxaban, warfarin): CE/BZA may be co-used with anticoagulation in some clinical scenarios, but this requires haematology or specialist input, not a self-managed restart.
• Corticosteroids prescribed during the illness: short courses do not require action; prolonged corticosteroid use independently increases VTE risk and affects bone metabolism, which changes the benefit-risk calculus for CE/BZA continuation.